Zhaojie Meng1, Rebecca Hernandez1, Jingwei Liu1, Taesik Gwag2, Weiwei Lu2, Tzung K Hsiai3, Marcus Kaul1, Tong Zhou4, Changcheng Zhou5. 1. Division of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA. 2. Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY, USA. 3. Departments of Medicine and Bioengineering, David Geffen School of Medicine, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, CA, USA. 4. Department of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV, USA. 5. Division of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA. changcheng.zhou@ucr.edu.
Abstract
PURPOSE: HIV infection is consistently associated with an increased risk of atherosclerotic cardiovascular disease, but the underlying mechanisms remain elusive. HIV protein Tat, a transcriptional activator of HIV, has been shown to activate NF-κB signaling and promote inflammation in vitro. However, the atherogenic effects of HIV Tat have not been investigated in vivo. Macrophages are one of the major cell types involved in the initiation and progression of atherosclerosis. We and others have previously revealed the important role of IκB kinase β (IKKβ), a central inflammatory coordinator through activating NF-κB, in the regulation of macrophage functions and atherogenesis. This study investigated the impact of HIV Tat exposure on macrophage functions and atherogenesis. METHODS: To investigate the effects of Tat on macrophage IKKβ activation and atherosclerosis development in vivo, myeloid-specific IKKβ-deficient LDLR-deficient (IKKβΔMyeLDLR-/-) mice and their control littermates (IKKβF/FLDLR-/-) were exposed to recombinant HIV protein Tat. RESULTS: Exposure to Tat significantly increased atherosclerotic lesion size and plaque vulnerability in IKKβF/FLDLR-/- but not IKKβΔMyeLDLR-/- mice. Deficiency of myeloid IKKβ attenuated Tat-elicited macrophage inflammatory responses and atherosclerotic lesional inflammation in IKKβΔMyeLDLR-/- mice. Further, RNAseq analysis demonstrated that HIV protein Tat affects the expression of many atherosclerosis-related genes in vitro in an IKKβ-dependent manner. CONCLUSIONS: Our findings reveal atherogenic effects of HIV protein Tat in vivo and demonstrate a pivotal role of myeloid IKKβ in Tat-driven atherogenesis.
PURPOSE: HIV infection is consistently associated with an increased risk of atherosclerotic cardiovascular disease, but the underlying mechanisms remain elusive. HIV protein Tat, a transcriptional activator of HIV, has been shown to activate NF-κB signaling and promote inflammation in vitro. However, the atherogenic effects of HIV Tat have not been investigated in vivo. Macrophages are one of the major cell types involved in the initiation and progression of atherosclerosis. We and others have previously revealed the important role of IκB kinase β (IKKβ), a central inflammatory coordinator through activating NF-κB, in the regulation of macrophage functions and atherogenesis. This study investigated the impact of HIV Tat exposure on macrophage functions and atherogenesis. METHODS: To investigate the effects of Tat on macrophage IKKβ activation and atherosclerosis development in vivo, myeloid-specific IKKβ-deficient LDLR-deficient (IKKβΔMyeLDLR-/-) mice and their control littermates (IKKβF/FLDLR-/-) were exposed to recombinant HIV protein Tat. RESULTS: Exposure to Tat significantly increased atherosclerotic lesion size and plaque vulnerability in IKKβF/FLDLR-/- but not IKKβΔMyeLDLR-/- mice. Deficiency of myeloid IKKβ attenuated Tat-elicited macrophage inflammatory responses and atherosclerotic lesional inflammation in IKKβΔMyeLDLR-/- mice. Further, RNAseq analysis demonstrated that HIV protein Tat affects the expression of many atherosclerosis-related genes in vitro in an IKKβ-dependent manner. CONCLUSIONS: Our findings reveal atherogenic effects of HIV protein Tat in vivo and demonstrate a pivotal role of myeloid IKKβ in Tat-driven atherogenesis.
Authors: Sonia Mediouni; Albert Darque; Gilbert Baillat; Isabelle Ravaux; Catherine Dhiver; Herve Tissot-Dupont; Malika Mokhtari; Herve Moreau; Catherine Tamalet; Corinne Brunet; Pascale Paul; Francoise Dignat-George; Andreas Stein; Philippe Brouqui; Stephen A Spector; Grant R Campbell; Erwann P Loret Journal: Infect Disord Drug Targets Date: 2012-02
Authors: Mike Veenstra; Desiree A Byrd; Matilde Inglese; Korhan Buyukturkoglu; Dionna W Williams; Lazar Fleysher; Ming Li; Lucio Gama; Rosiris León-Rivera; Tina M Calderon; Janice E Clements; Susan Morgello; Joan W Berman Journal: J Neuroimmune Pharmacol Date: 2018-07-06 Impact factor: 4.147
Authors: Erik Ehinger; Yanal Ghosheh; Akula Bala Pramod; Juan Lin; David B Hanna; Karin Mueller; Christopher P Durant; Livia Baas; Qibin Qi; Tao Wang; Konrad Buscher; Kathryn Anastos; Jason M Lazar; Wendy J Mack; Phyllis C Tien; Mardge H Cohen; Igho Ofotokun; Stephen Gange; Sonya L Heath; Howard N Hodis; Russell P Tracy; Alan L Landay; Robert C Kaplan; Klaus Ley Journal: Cardiovasc Res Date: 2021-03-21 Impact factor: 13.081